Lung Cancer News

Intensity-modulated proton therapy conferred durable control with minimal toxicity among patients with recurrent thoracic cancer, according to results of a retrospective study presented at the Multidisciplinary Thoracic Cancers Symposium.

Recommendations for surveillance after cancer treatment in survivors across guidelines are often nonspecific and inconsistent; therefore, clarification for or against the use of specific tests is warranted in current guidelines, according to findings published in JAMA Internal Medicine.

Ten percent of patients with lung cancer who received thoracic radiation therapy with immune checkpoint inhibitors experienced severe toxicities, according to a retrospective study presented at the Multidisciplinary Thoracic Cancers Symposium.

More than one in five patients with non–small cell lung cancer develop various types of genetic resistance during treatment and could benefit from additional biopsies to alter treatment, according to a study presented at the Multidisciplinary Thoracic Cancers Symposium.

The phase 1b trial designed to evaluate HS-110 in combination with nivolumab for the treatment of non–small cell lung cancer met its efficacy endpoint and will advance into a phase 2 trial, according to the drug’s manufacturer.

Use of annual lung cancer screenings with low-dose CT remains low among current and former smokers following the 2013 recommendations by the U.S. Preventive Services Task Force, according to a research letter published in JAMA Oncology.

When ordering advanced imaging procedures, such as radionuclide imaging, MRI and CT, physicians will soon be required to consult appropriate use criteria using CMS-approved computer-based clinical decision support mechanisms, due to an impending provision by CMS in the Protecting Access to Medicare Act, according to a commentary published in Annals of Internal Medicine.

Early integration of palliative care for patients with newly diagnosed incurable gastrointestinal and lung cancers improved quality of life, reduced depression symptoms, and enhanced coping with prognosis and communication about end-of-life preferences, according to a randomized clinical trial published in Journal of Clinical Oncology.

The benefits of oral contraceptives outweigh the harms, protecting against lifetime risks of certain cancers, including endometrial, ovarian and colorectal cancer, according to research published in the American Journal of Obstetrics and Gynecology.

The FDA granted priority review to a supplemental new drug application that seeks to expand the use of ceritinib to include first-line treatment of anaplastic lymphoma kinase–positive metastatic non–small cell lung cancer, according to the drug’s manufacturer.